Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

Iwasaki, Masanori; Hoshian, Fuminori; Tsuji, Tomoko; Hirose, Naoki; Matsumoto, Tomoko; Kitatani, Naomi; Sugawara, Kenji; Usui, Ryota; Kuwata, Hitoshi; Sugizaki, Kazu; Kitamoto, Yuka; Fujiwara, Sei; Watanabe, Koin; Hyo, Takanori; Kurose, Takeshi; Seino, Yutaka; Yabe, Daisuke

doi:10.1111/j.2040-1124.2012.00214.x

Cited by 31 publications

(29 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Iwasaki et al . found that the reduction of HbA1c by administration of DPP‐4 inhibitors as monotherapy significantly correlated with baseline levels of EPA and DHA, but not with that of AA, by the simple linear regression analysis, through unknown mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination

Shimoda

Iwashita

Sekigami

et al. 2013

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction: The goal of the study was to examine the effects of sitagliptin dose-up or glimepiride dose-up in Japanese patients with type 2 diabetes who were controlled inadequately by sitagliptin and glimepiride in combination. Materials and Methods: A multicenter, prospective, randomized, open-label study was carried out in 50 patients with type 2 diabetes treated with sitagliptin and low-dose glimepiride. The patients were randomly assigned to receive the addition of 50 mg/day sitagliptin or 0.5 mg/day glimepiride. The primary end-point was the percentage change in glycated hemoglobin (HbA1c). Results: During a follow-up period, the difference in the percentage changes in HbA1c between the two groups was not significant (P = 0.13). However, HbA1c was significantly decreased by glimepiride dose-up (P < 0.01 vs baseline), but not by sitagliptin dose-up (P = 0.74). Univariate linear regression analyses showed that the percentage change in HbA1c was significantly associated with the serum level of arachidonic acid (AA) in both groups. Conclusions: There was no significant difference in the HbA1c-lowering effects between the two groups. However, a significant HbA1c-lowering effect from baseline of glimepiride dose-up was found, and the AA level showed a negative correlation with the decrease in HbA1c in the sitagliptin dose-up group, but a positive correlation in the glimepiride dose-up group. These findings suggest that the AA level is associated with HbA1c reduction in response to dose-up with these drugs in patients with type 2 diabetes in a combination therapy with sitagliptin and glimepiride. This trial was registered with UMIN (no. 000009544).

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination

Shimoda

Iwashita

Sekigami

et al. 2013

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…In a study with healthy subjects, the consumption of a sandwich (containing bread, butter, and dried meat) was reported to strongly enhance GIP secretion and demonstrated the highest effectivity of incretin, compared to a meal consisting of dried meat or butter only . In addition, in Japanese type 2 diabetes patients, the effectiveness of glycated hemoglobin reduction by DPP‐4 inhibitor administration was increased with intake of fish, and this finding correlated to the amount of polyunsaturated fatty acids, such as docosahexaenoic acid and eicosapentaenoic acid, contained in the consumed fish .…”

Section: Glp‐1 Is a Crucial Target For Dietary Factors In Type 2 Diabmentioning

confidence: 99%

Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon‐like peptide‐1 secretion

Tsuda

2015

Molecular Nutrition Food Res

View full text Add to dashboard Cite

There is a pressing need for countermeasures against diabetes, which has increased in incidence, becoming a global issue. Glucagon-like peptide-1 (GLP-1), a molecule secreted in enteroendocrine L cells in the lower small and large intestines, is thought to be one of the most important molecular targets for the prevention and treatment of diabetes. There has been increasing interest in the possible ability of dietary factors to treat diabetes via modulating GLP-1 secretion. There is thought to be a close relationship between incretin and diet, and the purported best approach for using dietary factors to increase GLP-1 activity is promotion of secretion of endogenous GLP-1. It have been reported that nutrients as well as various non-nutrient dietary factors can function as GLP-1 secretogogues. Here, we present our findings on the GLP-1 secretion-stimulating functions of two dietary factors, curcumin and extract of edible sweet potato leaves, which contain caffeoylquinic acid derivatives. However, it is necessary to reveal in greater detail the stimulation of GLP-1 secretion by dietary factors for preventing and treating diabetes. It is desirable to clarify the exact GLP-1 secretory pathway, the effect of metabolites derived from dietary factors in gut lumen, and the relationship between incretin and meal.

show abstract

“…Differences in body mass index (BMI) across ethnic groups may mediate the HbA1c lowering efficacy of DPP-4 inhibitors. Iwasaki et al [34] demonstrated that the reduction of HbA1c by DPP-4 inhibitors showed a significant association with the estimated intake of fish in food records and serum levels of EPA and DHA in 72 untreated Japanese patients with type 2 diabetes, suggesting that the efficacy of this drug might be linked to the diet style (Japanese- vs. Western-style food).…”

Section: Drug Therapymentioning

confidence: 99%

The Prevalence and Management of Diabetic Nephropathy in Asia

Tomino

Gohda²

2015

Kidney Dis

View full text Add to dashboard Cite

Background: Diabetic nephropathy (DN), especially type 2 diabetes, is now increasing rapidly worldwide, also in Asian countries, and is one of the major long-term vascular complications. The pathogenesis of DN involves both genetic and environmental factors. Around 30-40% of type 2 diabetic patients develop DN despite strict blood glucose and/or blood pressure control. Although it is considered that the genetic background may influence the initiation and progression of DN, the candidate genes are still obscure. Summary: To search for genes that are involved in the susceptibility of DN, a candidate gene approach was taken in the beginning before the development of genome-wide association studies. Although a candidate gene approach can detect rare genetic variants, in advance we need known or presumed pathophysiological knowledge of the specific gene. Investigations using spontaneous animal models are important to determine the pathogenesis and treatment of DN patients. There are many spontaneous animal models, such as the NOD and Akita mice for type 1 diabetes and the Ob/Ob, db/db, Tsumura Suzuki Obese Diabetics, and KK-A^y mice for type 2 diabetes. Furthermore, the toxicity of persistent hyperglycemia, the activation of reactive oxygen species, systemic and/or glomerular hypertension, microinflammation, dyslipidemia, and other factors are considered to play important roles. Diabetic patients with normoalbuminuria and normal renal function showed typical histological patterns of DN. The discovery of a specific and reliable diagnostic and prognostic biomarker other than albuminuria is urgently needed and indispensable. Since large clinical trials of oral hypoglycemic drugs in renal failure are lacking, these recommendations will need to be regularly updated after results of larger randomized trials with longer follow-up durations are available. Key Messages: It is necessary to summarize the basic and clinical features of DN patients in Asia and to use these for the treatment of such patients. Facts from East and West: The prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme gene is associated with progression to end-stage renal disease in Asian patients with DN, but this association is uncertain in Europeans. An association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Both in Japan and the US, criteria for diagnosis are a 5-year history of diabetes and persistent albuminuria. Renal biopsy should be done in patients with severe hematuria, cellular casts and - in the US - hepatitis and HIV to rule out other pathologies. Diabetic retinopathy is considered a key criterion in Japan, but the absence of it does not rule out DN in the US. Enlargement of the kidney is observed as a diagnostic criterion in Japan. The differential use of renal biopsy as diagnostic tool might account for a different prevalence between Asian countries. Some Japanese diabe...

show abstract

Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

Cited by 31 publications

References 11 publications

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination

Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon‐like peptide‐1 secretion

The Prevalence and Management of Diabetic Nephropathy in Asia

Contact Info

Product

Resources

About